Correspondence | Published:

Cancer detection

Breast-screening trials are ethical

Nature volume 511, page 155 (10 July 2014) | Download Citation

The ethics have been questioned of running new randomized controlled trials to determine the benefits and possible harms of population screening for breast cancer (see go.nature.com/vw13jv). As an ethics representative on the Swiss Medical Board, I believe that there is a moral requirement for this type of study. We need to ascertain whether advances in treatment have cancelled out the benefits of early diagnosis through screening.

The random allocation of women into groups that have mammograms with different detection thresholds (see H. G. Welch The New York Times 29 December 2013; go.nature.com/scyt6b) or no mammogram would be ethically problematic if we knew that screening provided a significant net benefit. But this has not been established.

I contend that most women would prefer to participate in a trial that helps to clarify the benefit of screening, rather than continuing to be subjected to screening of doubtful benefit and with potential for significant harm through overdiagnosis.

Author information

Affiliations

  1. University of Zurich, Switzerland.

    • Nikola Biller-Andorno

Authors

  1. Search for Nikola Biller-Andorno in:

Corresponding author

Correspondence to Nikola Biller-Andorno.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/511155a

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing